Pre- and postdialytic blood pressures.

<p>Fig 2A-B is reused from our previous publication but is slightly modified compared to the original. Image reproduced under a CC-BY licence from [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0126882#pone.0126882.ref026" target="_blank">26</a>] with permission from Nature Publishing group. PreHD: Predialytic blood pressure (BP); PostHD: Postdialytic BP; Δ: PostHD-PreHD difference; *) 0.05><i>P</i>≥0.01 vs. baseline within the placebo or ARB group; †) 0.05><i>P</i> ≥0.01 placebo vs. ARB; ↕†) in Figs 2C-D indicates that parallel curves were assumed (Model 2). The constant mean differences (placebo-ARB) with 95% confidence interval were 6.2(0.5–11)mmHg; <i>P</i> = 0.03 (Δ(PostHD-PreHD)Systolic BP) and 3.0(0.1–6.0)mmHg; <i>P</i> = 0.04 (Δ(PostHD-PreHD)Diastolic BP). Note that Fig 2A shows all predialytic BP values recorded between baseline and 12 months, whereas the <i>P</i>-values given in 2A were based on values obtained at baseline, 1 week, 3 months, 6 months, 9 months, and 12 months, respectively from multivariate repeated meaurements analysis (xtmixed). Mean values from these time points are given in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0126882#pone.0126882.t002" target="_blank">Table 2</a>.</p

Change (∆) between baseline and 12 months for selected parameters.

<p>Change baseline-12 months (Δ) for selected parameters. Values are given as means with 95% confidence intervals (95% CI). Estimates and <i>P</i>-values were based on multivariate repeated measurements model (xtmixed) Model 1 assuming different development over time in the two groups (placebo and ARB).</p><p>a) HD-time and additional antihypertensive drugs besides placebo/ARB could not be analyzed with xtmixed due to many identical values. Differences within/between groups were therefore analyzed with paired/unpaired Student’s t-test. HD_START: Measurements performed within the first 30 minutes of the HD-session; HD_END: Measurements performed within the last 30 minutes of the HD-session; DDD: Defined daily doses; Ang2: Angiotensin II Hemoglobin conversion factor from g/dL to mmol/L is x 0.6206.</p><p>Change (∆) between baseline and 12 months for selected parameters.</p

Consort flow diagram.

<p>This figure is reused from our previous publication [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0126882#pone.0126882.ref026" target="_blank">26</a>]. Inclusion and exclusion criteria have been published previously [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0126882#pone.0126882.ref025" target="_blank">25</a>]. Briefly, the main inclusion criteria were urine output >300 mL/day, dialysis vintage <1 year and left ventricular ejection fraction >30%. Absence of an AV-fistula was not an exclusion criterion since most patients were expected to obtain an AV-fistula during the study. Moreover, blood pressure and IDH episodes were monitored in all patients regardless of access modality. Time of dropout was not significantly different as previously reported [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0126882#pone.0126882.ref026" target="_blank">26</a>].</p

Baseline characteristics.

<p>Data are presented as mean ± standard deviation or as median with range.</p><p>‡) Cardiovascular disease was defined as ≥ 1 known conditions (placebo/ARB): Ischemic heart disease (9/8); arrhythmia (6/5); valvular disease (6/3); heart failure (0/1); LV: Left ventricular;</p><p>#)Tx: Kidney transplantation;</p><p>§) Charlson comorbidity index score range 0–37; 0 = low, 3+ = high; DDD = Defined daily doses; EPO: erythropoetin;</p><p>a) n = 39 (Placebo group);</p><p>b) n = 36 (Placebo group);</p><p>GFR: glomerular filtration rate based on the mean of urinary creatinine and urea clearance as previously described [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0126882#pone.0126882.ref025" target="_blank">25</a>]; bpm: beats per minute; HDF: hemodiafiltration; HD: hemodialysis;</p><p>c) Three patients in the placebo group and two patients in the ARB group had dialysis vintage > one year and four patients (two in each group) had urine output < 300 mL/day due to delay after inclusion/screening.</p><p>Baseline characteristics.</p

Intradialytic hemodynamic changes.

<p>Δ = (HD_END—HD_START); HD_START: Intradialytic measurement within the first 30 minutes of dialysis; HD_END: Intradialytic measurement within the last 30 minutes of dialysis; CO: Cardiac output; MAP: Mean arterial blood pressure; HR: Heart rate; TPR: Total peripheral resistance; SV: Stroke volume; CBV: Central blood volume (volume of blood in the heart, lungs, and the great vessels). *) 0.05><i>P</i>>0.01 vs. baseline within the placebo or ARB group †) 0.05><i>P</i>>0.01 vs. placebo ‡) 0.01><i>P</i> >0.001 vs. placebo ↕†) Indicates that parallel curves were assumed (Model 2). The constant mean difference (placebo-ARB) with 95% confidence interval was 2.4(0.2.4.6) bpm (<i>P</i> = 0.03).</p